13.03.2013 - British Shire plc has broadened its therapeutic scope to neonatology by the strategic acquisition of Swedish Premacure AB of Uppsala.
The privately held biotech company is running a dose finding, safety and efficacy Phase II programme for the most common cause of visual loss in childhood – the prevention of retinopathy of prematurity (ROP). Currently, only symptomatic treatment is available for ROP. Shire will purchase Premacure for an undisclosed upfront fee and success-dependent milestones.
In ROP, preterm infants (born before 31 weeks of gestation) lack specific growth factors, such as insulin-like growth factor 1 (IGF-1), which supports normal childhood development and which is involved in ROP. The Swedish have developed a first-in-class recombinant protein replacement therapy termed rhIGF-I/rhIGFBP-3 (insulin-like growth factor-1 binding protein-3) for the orphan disease. The company believes administration of IGF-1 to premature infants, as a substitute for the maternal and endogenous source, allows for the establishment of a physiological level of the hormone comparable to that present in utero.
Shire said it will continue the ongoing Phase II study, the primary goal of which is to restore the IGF-1 levels in preterm infants to those found during normal in utero development. „ We will build on the work that Premacure has done and will apply Shire’s proven ability in developing protein replacement therapies for rare disorders to bring this much needed therapy to the market,” said Flemming Ornskov, CEO Designate of Shire. The treatment targets a patient population of 1,100–1,500 in the US alone .
28.11.2014 The first gene therapy for a rare genetic condition — UniQure's Glybera — is on its way to the European market. But there is a hefty price tag: Chiesi, responsible for the marketing of the orphan drug, is asking for a record price of €1.1m per patient.
25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.